LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 34.50 | 770.25 | 3522 | 3712 | 0.9488 | 0.9542 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 36.73 | 770.25 | 3245 | 4086 | 0.7942 | 0.8174 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 36.73 | 770.25 | 3890 | 4086 | 0.9520 | 0.9596 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 38.95 | 770.25 | 3437 | 4543 | 0.7564 | 0.7934 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 38.95 | 770.25 | 4182 | 4543 | 0.9204 | 0.9362 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 41.17 | 770.25 | 3692 | 5010 | 0.7368 | 0.7862 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 41.17 | 770.25 | 4550 | 5010 | 0.9081 | 0.9299 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 43.39 | 770.25 | 4063 | 5404 | 0.7518 | 0.8070 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 43.39 | 770.25 | 4958 | 5404 | 0.9174 | 0.9396 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 45.61 | 770.25 | 4358 | 5813 | 0.7497 | 0.8119 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 45.61 | 770.25 | 5409 | 5813 | 0.9305 | 0.9512 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 47.83 | 770.25 | 4710 | 6223 | 0.7568 | 0.8234 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 47.83 | 770.25 | 5883 | 6223 | 0.9453 | 0.9630 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 50.05 | 770.25 | 5036 | 6629 | 0.7596 | 0.8306 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 50.05 | 770.25 | 6300 | 6629 | 0.9503 | 0.9674 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 52.27 | 770.25 | 5348 | 7058 | 0.7576 | 0.8336 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 52.27 | 770.25 | 6576 | 7058 | 0.9316 | 0.9562 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 54.49 | 770.25 | 5674 | 7555 | 0.7510 | 0.8335 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 54.49 | 770.25 | 7043 | 7555 | 0.9322 | 0.9578 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 56.71 | 770.25 | 5999 | 8001 | 0.7497 | 0.8365 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 56.71 | 770.25 | 7386 | 8001 | 0.9231 | 0.9531 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 58.94 | 770.25 | 6308 | 8444 | 0.7470 | 0.8381 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 58.94 | 770.25 | 7671 | 8444 | 0.9084 | 0.9452 | MN20160304_L02 | J17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 61.16 | 770.25 | 6623 | 8892 | 0.7448 | 0.8398 | MN20160304_L02 | E17 |
| MCF 10A-H2B-mCherry | Dasatinib | 0.056667 | 61.16 | 770.25 | 8057 | 8892 | 0.9061 | 0.9449 | MN20160304_L02 | J17 |